Roger Song
Stock Analyst at Jefferies
(4.32)
# 353
Out of 5,147 analysts
53
Total ratings
52.17%
Success rate
20.87%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Roger Song
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BIOA BioAge Labs | Upgrades: Buy | $9 → $62 | $22.27 | +178.40% | 3 | Feb 18, 2026 | |
| KRYS Krystal Biotech | Maintains: Buy | $310 → $371 | $275.64 | +34.60% | 2 | Feb 17, 2026 | |
| PTGX Protagonist Therapeutics | Maintains: Buy | $95 → $118 | $92.08 | +28.15% | 1 | Feb 2, 2026 | |
| CRVS Corvus Pharmaceuticals | Maintains: Buy | $13 → $42 | $18.26 | +130.01% | 3 | Jan 22, 2026 | |
| NKTR Nektar Therapeutics | Maintains: Buy | $99 → $121 | $68.98 | +75.41% | 12 | Nov 26, 2025 | |
| ORKA Oruka Therapeutics | Initiates: Buy | $45 | $34.41 | +30.78% | 1 | Nov 13, 2025 | |
| GYRE Gyre Therapeutics | Initiates: Buy | $16 | $8.24 | +94.17% | 1 | Oct 10, 2025 | |
| UTHR United Therapeutics | Maintains: Buy | $432 → $564 | $503.90 | +11.93% | 1 | Sep 2, 2025 | |
| BMEA Biomea Fusion | Initiates: Buy | $5 | $1.37 | +264.96% | 1 | Aug 28, 2025 | |
| ATYR aTyr Pharma | Maintains: Buy | $9 → $17 | $0.96 | +1,671.20% | 2 | Aug 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $36 | $32.55 | +10.60% | 1 | Aug 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $45 → $54 | $44.49 | +21.38% | 3 | Jul 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $31 → $6 | $7.65 | -21.57% | 2 | Jul 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $6 | $1.31 | +358.02% | 1 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $7 | $4.21 | +66.27% | 1 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $26 | $13.93 | +86.65% | 1 | Feb 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $32 → $28 | $8.73 | +220.73% | 2 | Nov 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $2 → $7 | $2.87 | +143.90% | 1 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $89 | $66.62 | +33.59% | 1 | Oct 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $31 → $25 | $10.14 | +146.55% | 2 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $41 | $15.97 | +156.73% | 1 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $35 | $26.35 | +32.83% | 1 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $108 → $129 | $61.74 | +108.94% | 1 | Sep 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $2.5 → $8 | $5.37 | +48.98% | 3 | May 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $97 | $101.95 | -4.86% | 1 | Apr 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $110 | $33.84 | +225.06% | 1 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $35 | $4.31 | +712.06% | 1 | Aug 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $9 | $2.76 | +226.09% | 1 | Jul 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $210 | $20.47 | +925.89% | 1 | Sep 2, 2020 |
BioAge Labs
Feb 18, 2026
Upgrades: Buy
Price Target: $9 → $62
Current: $22.27
Upside: +178.40%
Krystal Biotech
Feb 17, 2026
Maintains: Buy
Price Target: $310 → $371
Current: $275.64
Upside: +34.60%
Protagonist Therapeutics
Feb 2, 2026
Maintains: Buy
Price Target: $95 → $118
Current: $92.08
Upside: +28.15%
Corvus Pharmaceuticals
Jan 22, 2026
Maintains: Buy
Price Target: $13 → $42
Current: $18.26
Upside: +130.01%
Nektar Therapeutics
Nov 26, 2025
Maintains: Buy
Price Target: $99 → $121
Current: $68.98
Upside: +75.41%
Oruka Therapeutics
Nov 13, 2025
Initiates: Buy
Price Target: $45
Current: $34.41
Upside: +30.78%
Gyre Therapeutics
Oct 10, 2025
Initiates: Buy
Price Target: $16
Current: $8.24
Upside: +94.17%
United Therapeutics
Sep 2, 2025
Maintains: Buy
Price Target: $432 → $564
Current: $503.90
Upside: +11.93%
Biomea Fusion
Aug 28, 2025
Initiates: Buy
Price Target: $5
Current: $1.37
Upside: +264.96%
aTyr Pharma
Aug 22, 2025
Maintains: Buy
Price Target: $9 → $17
Current: $0.96
Upside: +1,671.20%
Aug 15, 2025
Assumes: Buy
Price Target: $36
Current: $32.55
Upside: +10.60%
Jul 29, 2025
Maintains: Buy
Price Target: $45 → $54
Current: $44.49
Upside: +21.38%
Jul 22, 2025
Maintains: Buy
Price Target: $31 → $6
Current: $7.65
Upside: -21.57%
Apr 1, 2025
Initiates: Buy
Price Target: $6
Current: $1.31
Upside: +358.02%
Mar 14, 2025
Initiates: Buy
Price Target: $7
Current: $4.21
Upside: +66.27%
Feb 25, 2025
Initiates: Buy
Price Target: $26
Current: $13.93
Upside: +86.65%
Nov 21, 2024
Maintains: Buy
Price Target: $32 → $28
Current: $8.73
Upside: +220.73%
Nov 19, 2024
Upgrades: Buy
Price Target: $2 → $7
Current: $2.87
Upside: +143.90%
Oct 23, 2024
Initiates: Buy
Price Target: $89
Current: $66.62
Upside: +33.59%
Oct 16, 2024
Maintains: Buy
Price Target: $31 → $25
Current: $10.14
Upside: +146.55%
Oct 11, 2024
Initiates: Buy
Price Target: $41
Current: $15.97
Upside: +156.73%
Oct 8, 2024
Initiates: Buy
Price Target: $35
Current: $26.35
Upside: +32.83%
Sep 3, 2024
Maintains: Buy
Price Target: $108 → $129
Current: $61.74
Upside: +108.94%
May 6, 2024
Upgrades: Buy
Price Target: $2.5 → $8
Current: $5.37
Upside: +48.98%
Apr 17, 2024
Initiates: Buy
Price Target: $97
Current: $101.95
Upside: -4.86%
Mar 7, 2024
Initiates: Buy
Price Target: $110
Current: $33.84
Upside: +225.06%
Aug 31, 2022
Maintains: Buy
Price Target: $30 → $35
Current: $4.31
Upside: +712.06%
Jul 29, 2022
Initiates: Buy
Price Target: $9
Current: $2.76
Upside: +226.09%
Sep 2, 2020
Initiates: Buy
Price Target: $210
Current: $20.47
Upside: +925.89%